All In Biotech

Drug Trial Radar · NCT07007065

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 561 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

561

Planned (sponsor's estimate)

Start

Nov 5, 2025

Primary completion

Mar 2033

Study completion Mar 2033

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jun 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. The purpose of this study is to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD). Surabgene Lomparvovec (ABBV-RGX-314) is an investigational gene therapy being developed for the treatment of neovascular age-related macular degeneration (nAMD). Participants will be placed into 1 of 3 groups, called treatment arms. Each group receives different treatment. Adult participants aged 50 and older years with a diagnosis of previously treated nAMD will be enrolled. Around 561 participants will be enrolled in the study at approximately 150 sites worldwide. Participants in groups 1 and 2 will receive a single subretinal dose of ABBV-RGX-314. Participants in group 3 will receive Ranibizumab as needed throughout the study. Ranibizumab will be given as an intravitreal injection (injection into the jelly-like tissue that fills the eyeball injection), and ABBV-RGX-314 will be given as a subretinal (between the retina and the back of the eye) injection. The Assessment Period begins after randomization (1:1:1) to one of the ABBV-RGX-314 treatment groups or control at Week -2 and lasts up to 5 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular monthly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

  • Surabgene Lomparvovec (ABBV-RGX-314)Drug

    subretinal injection

  • Ranibizumab ControlDrug

    intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized intravitreal anti-VEGF injection rateTime frame: Up to Week 54
  2. Number of Participants Experiencing Adverse EventsTime frame: Up to 5 years

Locations

138 sites in 17 countries. Site status is shown where the registry gives one.

  • Barnet Dulaney Perkins Eye Center - Mesa /ID# 279265

    Mesa, Arizona · Recruiting

  • American Vision Partners /ID# 264615

    Sun City, Arizona · Recruiting

  • Retinal Diagnostic Center /ID# 263054

    Campbell, California · Recruiting

  • The Retina Partners /ID# 263265

    Encino, California · Recruiting

  • Retina Associates of Southern California /ID# 263056

    Huntington Beach, California · Recruiting

  • Shiley Eye Institute At Uc San Diego Health /ID# 276682

    La Jolla, California · Recruiting

  • Northern California Retina Vitreous Associates - Mountain View /ID# 263990

    Mountain View, California · Recruiting

  • Eye Research Foundation /ID# 277345

    Newport Beach, California · Recruiting

  • Retina Consultants of San Diego /ID# 264026

    Poway, California · Recruiting

  • Retina Consultants Of Southern California - Redlands /ID# 276496

    Redlands, California · Recruiting

  • Kaiser Permanente - Riverside Medical Center /ID# 263253

    Riverside, California · Recruiting

  • Retinal Consultants - Sacramento - Greenback Lane /ID# 263983

    Sacramento, California · Recruiting

  • UCSF, Wayne and Gladys Valley Center for Vision /ID# 263058

    San Francisco, California · Recruiting

  • Orange County Retina Medical Group /ID# 266612

    Santa Ana, California · Recruiting

  • Retina Consultants of Southern Colorado /ID# 263284

    Colorado Springs, Colorado · Recruiting

  • Colorado Retina Associates /ID# 263247

    Lakewood, Colorado · Recruiting

  • Advanced Vision Surgery Center /ID# 264208

    Longmont, Colorado · Recruiting

  • Advanced Research, LLC /ID# 276526

    Deerfield Beach, Florida · Recruiting

  • Segal Drug Trials, Inc /ID# 276966

    Delray Beach, Florida · Recruiting

  • Retina Vitreous Consultants LLP business DBA as Retina Group of Florida /ID# 264631

    Fort Myers, Florida · Recruiting

  • Florida Retina Institute - Orlando /ID# 263288

    Orlando, Florida · Recruiting

  • Center for Retina and Macular Disease /ID# 264201

    Winter Haven, Florida · Recruiting

  • Southeast Retina Center /ID# 263264

    Augusta, Georgia · Recruiting

  • Vision Medical Research /ID# 277102

    Oak Lawn, Illinois · Recruiting

  • Springfield Clinic Main Campus /ID# 265202

    Springfield, Illinois · Recruiting

  • Retina Partners Midwest, P.C. /ID# 264031

    Carmel, Indiana · Recruiting

  • Wolfe Eye Clinic - West Des Moines /ID# 263270

    West Des Moines, Iowa · Recruiting

  • Retina Associates - Lenexa /ID# 264607

    Lenexa, Kansas · Recruiting

  • Maine Eye Center - Marginal Way Campus /ID# 263251

    Portland, Maine · Recruiting

  • The Retina Care Center /ID# 263263

    Baltimore, Maryland · Recruiting

  • Retina Specialist /ID# 264633

    Towson, Maryland · Recruiting

  • Associated Retinal Consultants /ID# 263289

    Royal Oak, Michigan · Recruiting

  • Retina Consultants of Minnesota (RCM) - Edina Retina Clinic /ID# 279427

    Edina, Minnesota · Recruiting

  • Mayo Clinic - Minnesota /ID# 263977

    Rochester, Minnesota · Recruiting

  • Retina Institute - St. Louis /ID# 263985

    St Louis, Missouri · Recruiting

  • Sierra Eye Associates /ID# 263240

    Reno, Nevada · Recruiting

  • Monmouth Retina Consultants /ID# 279252

    Little Silver, New Jersey · Recruiting

  • Cleveland Clinic - Cleveland /ID# 264210

    Cleveland, Ohio · Recruiting

  • Ohio State Havener Eye Institute - Columbus /ID# 263987

    Columbus, Ohio · Recruiting

  • Midwest Retina /ID# 263231

    Dublin, Ohio · Recruiting

Showing 40 of 138 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.